Cystic fibrosis genetics: From molecular understanding to clinical application

Nature Reviews Genetics

Volumn 16, Issue 1, 2015, Pages 45-56

  Cutting, Garry R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE CHANNEL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; CFTR PROTEIN, HUMAN;

ANIMAL MODEL; CHLORIDE TRANSPORT; CTFR GENE; DISEASE SEVERITY; DNA MODIFICATION; GENE; GENE FUNCTION; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; LUNG CYSTIC FIBROSIS; LUNG FIBROSIS; MOLECULAR DIAGNOSIS; MOLECULAR GENETICS; MOLECULAR THERAPY; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; TISSUE CULTURE; BIOLOGICAL MODEL; CYSTIC FIBROSIS; GENE THERAPY; GENETIC VARIATION; GENETICS; MEDICAL GENETICS; PATHOPHYSIOLOGY; PHENOTYPE; PROCEDURES; TRENDS;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC THERAPY; GENETIC VARIATION; GENETICS, MEDICAL; HUMANS; MODELS, BIOLOGICAL; MOLECULAR DIAGNOSTIC TECHNIQUES; PHENOTYPE;

EID: 84927176500     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg3849     Document Type: Review

References (147)

1. MacKenzie, T. et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the cystic fibrosis foundation patient registry. Ann. Intern. Med. 161, 233-241 (2014).
2. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2011 (Cystic Fibrosis Foundation, 2012).
3. Rommens, J. M. et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245, 1059-1065 (1989).
4. Riordan, J. R. et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066-1073 (1989).
5. Kerem, B. et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245, 1073-1080 (1989).
6. Kartner, N. et al. Expression of the cystic fibrosis gene in non-epithelial invertebrate cells produces a regulated anion conductance. Cell 64, 681-691 (1991).
7. Quinton, P. M. Chloride impermeability in cystic fibrosis. Nature 301, 421-422 (1983).
8. Knowles, M. R. et al. Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 221, 1067-1070 (1983).
9. Welsh, M. J. & Smith, A. E. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73, 1251-1254 (1993).
10. Rich, D. P. et al. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 347, 358-363 (1990).
11. Guggino, W. B. & Stanton, B. A. New insights into cystic fibrosis: molecular switches that regulate CFTR. Nature Rev. Mol. Cell. Biol. 7, 426-436 (2006).
12. Moskowitz, S. M. et al. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet. Med. 10, 851-868 (2008).
13. Zielenski, J. Genotype and phenotype in cystic fibrosis. Respiration 67, 117-133 (2000).
14. Bombieri, C. et al. Recommendations for the classification of diseases as CFTR-related disorders. J. Cyst. Fibros. 10 (Suppl. 2), S86-S102 (2011).
15. Ramsey, B. W. et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663-1672 (2011).
16. Boyle, M. P. et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir. Med. 2, 527-538 (2014).
17. Cheng, S. H. et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63, 827-834 (1990).
18. Denning, G. M. et al. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358, 761-764 (1992).
19. Lazrak, A. et al. The silent codon change I507-ATC→ATT contributes to the severity of the δF508 CFTR channel dysfunction. FASEB J. 27, 4630-4645 (2013).
20. Sosnay, P. R. et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nature Genet. 45, 1160-1167 (2013).
21. Van Goor, F., Yu, H., Burton, B. & Hoffman, B. J. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J. Cyst. Fibros. 13, 29-36 (2014).
22. Lukacs, G. L. & Verkman, A. S. CFTR: folding, misfolding and correcting the δF508 conformational defect. Trends Mol. Med. 18, 81-91 (2012).
23. Seibert, F. S. et al. Disease-associated mutations in the fourth cytoplasmic loop of cystic fibrosis transmembrane conductance regulator compromise biosynthetic processing and chloride channel activity. J. Biol. Chem. 271, 15139-15145 (1996).
24. Cotten, J. F., Ostedgaard, L. S., Carson, M. R. & Welsh, M. J. Effect of cystic fibrosis-associated mutations in the fourth intracellular loop of cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 271, 21279-21284 (1996).
25. Mendoza, J. L. & Thomas, P. J. Building an understanding of cystic fibrosis on the foundation of ABC transporter structures. J. Bioenerg. Biomembr. 39, 499-505 (2007).
26. Mornon, J. P., Lehn, P. & Callebaut, I. Atomic model of human cystic fibrosis transmembrane conductance regulator: membrane-spanning domains and coupling interfaces. Cell. Mol. Life Sci. 65, 2594-2612 (2008).
27. Serohijos, A. W. et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc. Natl Acad. Sci. USA 105, 3256-3261 (2008).
28. Thibodeau, P. H. et al. The cystic fibrosis-causing mutation δF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J. Biol. Chem. 285, 35825-35835 (2010).
29. Krasnov, K. V., Tzetis, M., Cheng, J., Guggino, W. B. & Cutting, G. R. Localization studies of rare missense mutations in cystic fibrosis transmembrane conductance regulator (CFTR) facilitate interpretation of genotype-phenotype relationships. Hum. Mutat. 29, 1364-1372 (2008).
30. Rabeh, W. M. et al. Correction of both NBD1 energetics and domain interface is required to restore δF508 CFTR folding and function. Cell 148, 150-163 (2012).
31. Mendoza, J. L. et al. Requirements for efficient correction of δF508 CFTR revealed by analyses of evolved sequences. Cell 148, 164-174 (2012).
32. Okiyoneda, T. et al. Mechanism-based corrector combination restores δF508-CFTR folding and function. Nature Chem. Biol. 9, 444-454 (2013).
33. Matsui, H. et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95, 1005-1015 (1998).
34. Wong, A. P. et al. Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. Nature Biotech. 30, 876-882 (2012).
35. Dekkers, J. F. et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nature Med. 19, 939-945 (2013).
36. Schwank, G. et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13, 653-658 (2013).
37. Suprynowicz, F. A. et al. Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. Proc. Natl Acad. Sci. USA 109, 20035-20040 (2012).
38. Snouwaert, J. N. et al. An animal model for cystic fibrosis made by gene targeting. Science 257, 1083-1088 (1992).
39. Tuggle, K. L. et al. Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-knockout rats. PLoS ONE 9, e91253 (2014).
40. Sun, X. et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J. Clin. Invest. 120, 3149-3160 (2010).
41. Rogers, C. S. et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 321, 1837-1841 (2008).
42. Navis, A., Marjoram, L. & Bagnat, M. Cftr controls lumen expansion and function of Kupffer's vesicle in zebrafish. Development 140, 1703-1712 (2013).
43. Wilke, M. et al. Mouse models of cystic fibrosis: phenotypic analysis and research applications. J. Cyst. Fibros. 10, S152-S171 (2011).
44. Grubb, B. R. & Boucher, R. C. Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol. Rev. 79, S193-S214 (1999).
45. Clarke, L. B. et al. Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in CFTR-/- mice. Proc. Natl Acad. Sci. USA 91, 479-483 (1994).
46. Rock, J. R. et al. Transmembrane protein 16A (TMEM16A) is a Ca2+-regulated Cl- secretory channel in mouse airways. J. Biol. Chem. 284, 14875-14880 (2009).
47. Henderson, L. B. et al. Variation in MSRA modifies risk of neonatal intestinal obstruction in cystic fibrosis. PLoS Genet. 8, e1002580 (2012).
48. Keiser, N. W. & Engelhardt, J. F. New animal models of cystic fibrosis: what are they teaching us? Curr. Opin. Pulm. Med. 17, 478-483 (2011).
49. Rogers, C. S. et al. Production of CFTR-null and CFTR-δF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer. J. Clin. Invest. 118, 1571-1577 (2008).
50. Stoltz, D. A. et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci. Transl. Med. 2, 29ra31 (2010).
51. Khan, T. Z. et al. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 151, 1075-1082 (1995).
52. Pezzulo, A. A. et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487, 109-113 (2012).
53. Adam, R. J. et al. Air trapping and airflow obstruction in newborn cystic fibrosis piglets. Am. J. Respir. Crit. Care Med. 188, 1434-1441 (2013).
54. Chen, J. H. et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 143, 911-923 (2010).
55. Hodges, C. A., Grady, B. R., Mishra, K., Cotton, C. U. & Drumm, M. L. Cystic fibrosis growth retardation is not correlated with loss of Cftr in the intestinal epithelium. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G528-G536 (2011).
56. Stoltz, D. A. et al. Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs. J. Clin. Invest. 123, 2685-2693 (2013).
57. Ode, K. L. & Moran, A. New insights into cystic fibrosis-related diabetes in children. Lancet Diabetes Endocrinol. 1, 52-58 (2013).
58. Olivier, A. K. et al. Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets. J. Clin. Invest. 122, 3755-3768 (2012).
59. Uc, A. et al. Glycaemic regulation and insulin secretion are abnormal in cystic fibrosis pigs despite sparing of islet cell mass. Clin. Sci. (Lond.) 128, 131-142 (2015).
60. Kerem, E. et al. The relation between genotype and phenotype in cystic fibrosis-analysis of the most common mutation (δF508). N. Engl. J. Med. 323, 1517-1522 (1990).
61. The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N. Engl. J. Med. 329, 1308-1313 (1993).
62. Wilschanski, M. et al. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J. Pediatr. 127, 705-710 (1995).
63. McKone, E. F., Goss, C. H. & Aitken, M. L. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 130, 1441-1447 (2006).
64. Gan, K.-H. et al. A cystic fibrosis mutation associated with mild lung disease. N. Engl. J. Med. 333, 95-99 (1995).
65. Mekus, F. et al. Categories of δF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics. Twin. Res. 3, 277-293 (2000).
66. Vanscoy, L. L. et al. Heritability of lung disease severity in cystic fibrosis. Am. J. Respir. Crit. Care Med. 175, 1036-1043 (2007).
67. Collaco, J. M., Blackman, S. M., McGready, J., Naughton, K. M. & Cutting, G. R. Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function. J. Pediatr. 157, 802-807 (2010).
68. Li, Z. et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293, 581-588 (2005).
69. Green, D. M. et al. Heritability of respiratory infection with Pseudomonas aeruginosa in cystic fibrosis. J. Pediatr. 161, 290-295 (2012).
70. Bradley, G. M., Blackman, S. M., Watson, C. P., Doshi, V. K. & Cutting, G. R. Genetic modifiers of nutritional status in cystic fibrosis. Am. J. Clin. Nutr. 96, 1299-1308 (2012).
71. Stanke, F. et al. Genes that determine immunology and inflammation modify the basic defect of impaired ion conductance in cystic fibrosis epithelia. J. Med. Genet. 48, 24-31 (2011).
72. Blackman, S. M. et al. Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis. J. Clin. Endocrinol. Metab. 94, 1302-1309 (2009).
73. Finkelstein, S. M. et al. Diabetes mellitus associated with cystic fibrosis. J. Pediatr. 112, 373-377 (1988).
74. Rozmahel, R. et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nature Genet. 12, 280-287 (1996).
75. Blackman, S. M. et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology 131, 1030-1039 (2006).
76. Weiler, C. A. & Drumm, M. L. Genetic influences on cystic fibrosis lung disease severity. Front. Pharmacol. 4, 40 (2013).
77. Cutting, G. R. Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann. NY Acad. Sci. 1214, 57-69 (2010).
78. Knowles, M. R. & Drumm, M. The influence of genetics on cystic fibrosis phenotypes. Cold Spring Harb. Perspect. Med 2, a009548 (2012).
79. Drumm, M. L., Ziady, A. G. & Davis, P. B. Genetic variation and clinical heterogeneity in cystic fibrosis. Annu. Rev. Pathol. 7, 267-282 (2012).
80. Guillot, L. et al. Lung disease modifier genes in cystic fibrosis. Int. J. Biochem. Cell Biol. 52, 83-93 (2014).
81. Drumm, M. L. et al. Gene modifiers of lung disease in cystic fibrosis. N. Engl. J. Med. 353, 1443-1453 (2005).
82. Bremer, L. A. et al. Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. Hum. Mol. Genet. 17, 2228-2237 (2008).
83. Chalmers, J. D., Fleming, G. B., Hill, A. T. & Kilpatrick, D. C. Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: a review and meta-analysis. Glycobiology 21, 271-282 (2011).
84. Dorfman, R. et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J. Clin. Invest. 118, 1040-1049 (2008).
85. Collaco, J. M. et al. Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease. JAMA 299, 417-424 (2008).
86. Wright, F. A. et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nature Genet. 43, 539-546 (2011).
87. Blackman, S. M. et al. Genetic modifiers of cystic fibrosis-related diabetes. Diabetes 62, 3627-3635 (2013).
88. Bartlett, J. R. et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA 302, 1076-1083 (2009).
89. Sun, L. et al. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nature Genet. 44, 562-569 (2012).
90. Li, W. et al. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. Hum. Genet. 133, 151-161 (2014).
91. Emond, M. J. et al. Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nature Genet. 44, 886-889 (2012).
92. Luciani, A. et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nature Cell Biol. 12, 863-875 (2010).
93. Grody, W. W. et al. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet. Med. 3, 149-154 (2001).
94. Grody, W. W., Cutting, G. R. & Watson, M. S. The cystic fibrosis mutation "arms race": when less is more. Genet. Med. 9, 739-744 (2007).
95. Kelley, T. J., Al Nakkash, L., Cotton, C. U. & Drumm, M. L. Activation of endogenous δF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition. J. Clin. Invest. 98, 513-520 (1996).
96. Van Goor, F. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl Acad. Sci. USA 106, 18825-18830 (2009).
97. Jih, K. Y. & Hwang, T. C. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc. Natl Acad. Sci. USA 110, 4404-4409 (2013).
98. Eckford, P. D., Li, C., Ramjeesingh, M. & Bear, C. E. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J. Biol. Chem. 287, 36639-36649 (2012).
99. Accurso, F. J. et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N. Engl. J. Med. 363, 1991-2003 (2010).
100. Char, J. E. et al. A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor. PLoS ONE 9, e88564 (2014).
101. Accurso, F. J. et al. Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. J. Cyst. Fibros. 13, 139-147 (2014).
102. Van Goor, F. et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl Acad. Sci. USA 108, 18843-18848 (2011).
103. Clancy, J. P. et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67, 12-18 (2012).
104. Cholon, D. M. et al. Potentiator ivacaftor abrogates pharmacological correction of δF508 CFTR in cystic fibrosis. Sci. Transl Med. 6, 246ra96 (2014).
105. Veit, G. et al. Some gating potentiators, including VX-770, diminish δF508-CFTR functional expression. Sci. Transl Med. 6, 246ra97 (2014).
106. Phuan, P. W. et al. Synergy-based small-molecule screen using a human lung epithelial cell line yields δF508-CFTR correctors that augment VX-809 maximal efficacy. Mol. Pharmacol. 86, 42-51 (2014).
107. De Boeck, K. et al. CFTR biomarkers: time for promotion to surrogate end-point. Eur. Respir. J. 41, 203-216 (2013).
108. Yu, H. et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J. Cyst. Fibros. 11, 237-245 (2012).
109. Dietz, H. C. New therapeutic approaches to mendelian disorders. N. Engl. J. Med. 363, 852-863 (2010).
110. Mendell, J. T., Sharifi, N. A., Meyers, J. L., Martinez-Murillo, F. & Dietz, H. C. Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nature Genet. 36, 1073-1078 (2004).
111. Howard, M., Frizzell, R. A. & Bedwell, D. M. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Med. 2, 467-469 (1996).
112. Kerem, E. et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372, 719-727 (2008).
113. Kerem, E. et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir. Med. 2, 539-547 (2014).
114. Oren, Y. S. et al. The unfolded protein response affects readthrough of premature termination codons. EMBO Mol. Med. 6, 685-701 (2014).
115. Havens, M. A., Duelli, D. M. & Hastings, M. L. Targeting RNA splicing for disease therapy. Wiley. Interdiscip. Rev. RNA. 4, 247-266 (2013).
116. Griesenbach, U. & Alton, E. W. Moving forward: cystic fibrosis gene therapy. Hum. Mol. Genet. 22, R52-R58 (2013).
117. Falconer, D. S. & Mackay, T. F. C. Heritability in Introduction to Quantitative Genetics 160-183 (Pearson Education Limited, 1996).
118. Anguiano, A. et al. Congenital bilateral absence of the vas deferens - a primarily genital form of cystic fibrosis. JAMA 267, 1794-1797 (1992).
119. Gilljam, M. et al. Airway inflammation and infection in congenital bilateral absence of the vas deferens. Am. J. Respir. Crit. Care Med. 169, 174-179 (2003).
120. Colin, A. A. et al. Pulmonary function and clinical observations in men with congenital bilateral absence of the vas deferens. Chest 110, 440-445 (1996).
121. Chillón, M. et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N. Engl. J. Med. 332, 1475-1480 (1995).
122. Noone, P. G. & Knowles, M. R. 'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir. Res. 2, 328-332 (2001).
123. Ooi, C. Y. et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology 140, 153-161 (2011).
124. Larusch, J., Solomon, S. & Whitcomb, D. C. Pancreatitis Overview [online], http://www.ncbi.nlm. nih.gov/books/NBK190101/ (2014).
125. Larusch, J. et al. Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis. PLoS Genet. 10, e1004376 (2014).
126. Park, H. W. et al. Dynamic regulation of CFTR bicarbonate permeability by [Cl-]i and its role in pancreatic bicarbonate secretion. Gastroenterology 139, 620-631 (2010).
127. Kim, R. D. et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am. J. Respir. Crit. Care Med. 178, 1066-1074 (2008).
128. Knutsen, A. P. & Slavin, R. G. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin. Dev. Immunol. 2011, 843763 (2011).
129. Wang, X. et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 284, 1814-1819 (2000).
130. Wang, X. J., Kim, J., McWilliams, R. & Cutting, G. R. Increased prevalence of chronic rhinosinusitis in carriers of a cystic fibrosis mutation. Arch. Otolaryngol. Head Neck Surg. 131, 237-240 (2005).
131. Ooi, C. Y. et al. Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis? Thorax 69, 254-260 (2014).
132. Cutting, G. R. Annotating DNA variants is the next major goal for human genetics. Am. J. Hum. Genet. 94, 5-10 (2014).
133. Amaral, M. D. Processing of CFTR: traversing the cellular maze - how much CFTR needs to go through to avoid cystic fibrosis? Pediatr. Pulmonol. 39, 479-491 (2005).
134. Highsmith, W. E. Jr et al. Identification of a splice site mutation (2789 + 5GA) associated with small amounts of normal CFTR mRNA and mild cystic fibrosis. Hum. Mutat. 9, 332-338 (1997).
135. Ramalho, A. S. et al. Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am. J. Respir. Cell. Mol. Biol. 27, 619-627 (2002).
136. Chu, C.-S., Trapnell, B. C., Curristin, S. M., Cutting, G. R. & Crystal, R. G. Extensive post-translational deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis. J. Clin. Invest. 90, 785-790 (1992).
137. Rave-Harel, N. et al. The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. Am. J. Hum. Genet. 60, 87-94 (1997).
138. Johnson, L. G. et al. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nature Genet. 2, 21-25 (1993).
139. Zhang, L. et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS. Biol. 7, e1000155 (2009).
140. Romey, M. C. et al. A naturally occurring sequence variation that creates a YY1 element is associated with increased cystic fibrosis transmembrane conductance regulator gene expression. J. Biol. Chem. 275, 3561-3567 (2000).
141. Highsmith, W. E. Jr et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N. Engl. J. Med. 331, 974-980 (1994).
142. Hamosh, A., Rosenstein, B. J. & Cutting, G. R. CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells. Hum. Mol. Genet. 1, 542-544 (1992).
143. Silvis, M. R. et al. A mutation in the cystic fibrosis transmembrane conductance regulator generates a novel internalization sequence and enhances endocytic rates. J. Biol. Chem. 278, 11554-11560 (2003).
144. Wang, Y., Wrennall, J. A., Cai, Z., Li, H. & Sheppard, D. N. Understanding how cystic fibrosis mutations disrupt CFTR function: from single molecules to animal models. Int. J. Biochem. Cell Biol. 52, 47-57 (2014).
145. Friedman, K. J. et al. Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J. Biol. Chem. 274, 36193-36199 (1999).
146. Xue, X. et al. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am. J. Respir. Cell Mol. Biol. 50, 805-816 (2014).
147. Meyerholz, D. K. et al. Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children. Am. J. Respir. Crit. Care Med. 182, 1251-1261 (2010).